Deargen
Latest round
- Series B
Last raised
- Feb 2022
Total raised
- $22M
Investors
- 7
About Deargen
Based in Daejeon, South Korea, and founded in 2016, Deargen Inc. is an AI-powered drug design biotech company that discovers new disease targets through artificial intelligence technology and applies it to develop treatment strategies for precision medicine by designing small molecules for new drugs. In February 2022, Deargen Inc.S., Korea Development Bank, Nvestor, and The Wells Investment. As of February 2022, Kilsoo Kang is the CEO of Deargen Inc. Deargen’s product line includes drugs for the treatment of cardiovascular and metabolic diseases, neurological diseases, immune diseases, as well as anticancer drugs. The company is also running a 4D program, which is a new drug development pipeline from the discovery of hit substances. The 4D program includes DG-ONCO-T1, DG-ONCO-T2, DG-ONCO-T3, DG-ONCO-T4, DG-HF-T1, DG-HL-T1, and DG-ALS-T1. In addition, the company is also developing new drugs, such as NASH - target1, NASH - target2, NASH - target3, IPF - target1, IPF - target2, IPF - target3, IPF - target4, oncology, immunology, Hearing Loss, Alzheimer’s - target1, Alzheimer’s - target2, Alzheimer’s - target3, Alzheimer’s - target4, Alzheimer’s - target4, and more drugs through co-developed program.UG, an AI platform for new drug development based on its deep learning technology specializing in genome data analysis, biomarker prediction, molecule selection, and optimization.
Who invested in Deargen
7 investors across 3 rounds
See all investors in Deargen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Deargen
Who invested in Deargen?
Deargen has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Deargen raised?
Deargen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Deargen last raise money?
Deargen's most recent round on record is a Series B, in Feb 2022.
What does Deargen do?
Based in Daejeon, South Korea, and founded in 2016, Deargen Inc.
Where is Deargen headquartered?
Deargen is headquartered in Daejeon, South Korea.
Which VCs invest in companies like Deargen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Deargen's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Deargen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.